LRMR · Larimar Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| James E. Flynn 10% Owner | ▲ Buy | Open Market | 6,207,982 Shares held | 2/27/2026 | View profile |
| Hamilton Thomas Edward Director | ▲ Buy | Open Market | 714,798 Shares held | 7/6/2026 | View profile |
| BEN-MAIMON CAROLE President and CEO | ▲ Buy | Grant | 368,276 Shares held | 1/26/2026 | View profile |
| Celano Michael Director | ▲ Buy | Grant | 215,785 Shares held | 1/26/2026 | View profile |
| Shankar Gopi Chief Development Officer | ▲ Buy | Grant | 76,443 Shares held | 1/26/2026 | View profile |
| Clayton Russell Chief Medical Officer | ▲ Buy | Grant | 71,443 Shares held | 1/26/2026 | View profile |
| THOMAS FRANK E Director | ▲ Buy | Open Market | 7,000 Shares held | 2/27/2026 | View profile |
| SHERMAN JEFFREY W Director | ▲ Buy | Open Market | 5,000 Shares held | 2/27/2026 | View profile |
| Truitt Joseph Director | ▲ Buy | Open Market | 2,750 Shares held | 5/17/2023 | View profile |
Transaction History
| Hamilton Thomas Edward | ▲ Buy | Open Market | 50,000 | $167K | 7/6/2026 |
| James E. Flynn | ▲ Buy | Open Market | 1,084,010 | $5.4M | 2/27/2026 |
| James E. Flynn | ▲ Buy | Open Market | 831,978 | $4.2M | 2/27/2026 |
| James E. Flynn | ▲ Buy | Open Market | 2,000,000 | $10.0M | 2/27/2026 |
| James E. Flynn | ▲ Buy | Open Market | 1,084,012 | $5.4M | 2/27/2026 |
| SHERMAN JEFFREY W | ▲ Buy | Open Market | 5,000 | $25K | 2/27/2026 |
| THOMAS FRANK E | ▲ Buy | Open Market | 5,000 | $25K | 2/27/2026 |
| Hamilton Thomas Edward | ▲ Buy | Open Market | 100,000 | $500K | 2/27/2026 |
| Shankar Gopi | ▲ Buy | Grant | 25,637 | $0 | 1/26/2026 |
| Clayton Russell | ▲ Buy | Grant | 25,637 | $0 | 1/26/2026 |
| BEN-MAIMON CAROLE | ▲ Buy | Grant | 100,100 | $0 | 1/26/2026 |
| Celano Michael | ▲ Buy | Grant | 37,604 | $0 | 1/26/2026 |
| James E. Flynn | ▲ Buy | Open Market | 3,387,539 | $10.8M | 7/31/2025 |
| James E. Flynn | ▲ Buy | Open Market | 2,599,932 | $8.3M | 7/31/2025 |
| James E. Flynn | ▲ Buy | Open Market | 3,387,529 | $10.8M | 7/31/2025 |
| Celano Michael | ▲ Buy | Grant | 34,185 | $0 | 1/22/2025 |
| BEN-MAIMON CAROLE | ▲ Buy | Grant | 91,000 | $0 | 1/22/2025 |
| Clayton Russell | ▲ Buy | Grant | 23,306 | $0 | 1/22/2025 |
| Shankar Gopi | ▲ Buy | Grant | 23,306 | $0 | 1/22/2025 |
| Hamilton Thomas Edward | ▲ Buy | Open Market | 57,208 | $500K | 2/16/2024 |
| James E. Flynn | ▲ Buy | Open Market | 1,430,206 | $12.5M | 2/16/2024 |
| James E. Flynn | ▲ Buy | Open Market | 1,430,205 | $12.5M | 2/16/2024 |
| James E. Flynn | ▲ Buy | Open Market | 1,430,206 | $12.5M | 2/16/2024 |
| THOMAS FRANK E | ▲ Buy | Open Market | 2,000 | $22K | 2/14/2024 |
| Celano Michael | ▲ Buy | Grant | 31,250 | $0 | 1/17/2024 |
| BEN-MAIMON CAROLE | ▲ Buy | Grant | 66,125 | $0 | 1/17/2024 |
| Clayton Russell | ▲ Buy | Grant | 22,500 | $0 | 1/17/2024 |
| Shankar Gopi | ▲ Buy | Grant | 22,500 | $0 | 1/17/2024 |
| Shankar Gopi | ▲ Buy | Open Market | 5,000 | $19K | 12/7/2023 |
| Celano Michael | ▲ Buy | Open Market | 5,000 | $19K | 5/17/2023 |
| BEN-MAIMON CAROLE | ▲ Buy | Open Market | 5,000 | $19K | 5/17/2023 |
| Truitt Joseph | ▲ Buy | Open Market | 2,750 | $10K | 5/17/2023 |
| Celano Michael | ▲ Buy | Grant | 76,000 | $0 | 1/31/2023 |
| BEN-MAIMON CAROLE | ▲ Buy | Grant | 205,000 | $0 | 1/31/2023 |
| James E. Flynn | ▲ Buy | Open Market | 2,777,777 | $8.7M | 9/16/2022 |
| James E. Flynn | ▲ Buy | Open Market | 2,777,777 | $8.7M | 9/16/2022 |
| James E. Flynn | ▲ Buy | Open Market | 2,777,777 | $8.7M | 9/16/2022 |
| Hamilton Thomas Edward | ▲ Buy | Open Market | 317,460 | $1000K | 9/16/2022 |
| BEN-MAIMON CAROLE | ▲ Buy | Open Market | 31,746 | $100K | 9/16/2022 |
| Celano Michael | ▲ Buy | Open Market | 31,746 | $100K | 9/16/2022 |
| James E. Flynn | ▲ Buy | Open Market | 2,777,777 | $8.7M | 9/16/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Larimar Therapeutics Names John Harlow as President and COO
Larimar Therapeutics has appointed John Harlow as its new President and Chief Operating Officer, effective September 29. This leadership change is intended to strengthen the company's executive team. The stock is currently trading near its 52-week low, which provides context for this operational update.
Larimar Therapeutics Names John Harlow as President and COO. Larimar Therapeutics has appointed John Harlow as its new President and Chief Operating Officer, effective September 29. This leadership change is intended to strengthen the company's executive team. The stock is currently trading near its 52-week low, which provides context for this operational update.